



Regulus Therapeutics Inc.  
 Investor Relations Department  
 10614 Science Center Dr  
 San Diego, CA 92121  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: RGLS**

Last Trade:	0.95
Trade Time:	1:04 PM ET Jul 21, 2017
Change:	0.07 <span style="color: green;">↑</span> (+8.205%)
Day Range	0.88 - 0.97
52-Week Range	0.86 - 4.25
Volume	411,479

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*<sup>SM</sup> biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Jul 19, 2017 [Regulus Announces Pricing of Public Offering of Common Stock](#)
- Jul 19, 2017 [Regulus Announces Commencement of Public Offering of Common Stock](#)
- Jun 13, 2017 [Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer](#)
- Jun 12, 2017 [Regulus Announces Pipeline Updates and Advancements](#)
- Jun 1, 2017 [Pascale Witz Joins Regulus Board of Directors](#)

**Financials** [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 3, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 2, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 3, 2016 [Quarterly Report \(10-Q\)](#)